Device Trial Radar · NCT05981911
Evaluation of Effectiveness and Safety of Xience Skypoint Stents in Routine Clinical Practice
Last checked: Nov 21, 2026Latest source record: Jan 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,000
Planned (sponsor's estimate)
Start
Dec 14, 2023
Primary completion
Jun 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Seung-Jung ParkAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- CardioVascular Research Foundation, Korea
- First posted
- Aug 8, 2023
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the effectiveness and safety of XIENCE Skypoint stents in comparison to other drug-eluting stents (DES) in real-world practice.
Conditions
- Coronary Artery Disease
Interventions
XIENCE Skypoint™ stentDevice
Percutaneous coronary intervention with Xience-Skypoint™ stent
Primary outcomes
What the sponsor says the trial is designed to measure.
- the composite event rate of death, nonfatal myocardial infarction (MI), or ischemic-driven Target- Vessel Revascularization (TVR)Time frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Asan Medical Hospital
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.